RIGEL PHARMACEUTICALS INC (RIGL) Fundamental Analysis & Valuation

NASDAQ:RIGL • US7665597024

28.07 USD
-0.8 (-2.77%)
At close: Mar 9, 2026
28.6001 USD
+0.53 (+1.89%)
After Hours: 3/9/2026, 8:00:02 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This RIGL fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

7

RIGL gets a fundamental rating of 7 out of 10. The analysis compared the fundamentals against 519 industry peers in the Biotechnology industry. RIGL has an excellent financial health rating, but there are some minor concerns on its profitability. RIGL has both an excellent growth and valuation score. This means it is growing and it is still cheap. This is a rare combination! These ratings would make RIGL suitable for value and growth investing!


Dividend Valuation Growth Profitability Health

6

1. RIGL Profitability Analysis

1.1 Basic Checks

  • In the past year RIGL was profitable.
  • RIGL had a positive operating cash flow in the past year.
  • In the past 5 years RIGL reported 4 times negative net income.
  • The reported operating cash flow has been mixed in the past 5 years: RIGL reported negative operating cash flow in multiple years.
RIGL Yearly Net Income VS EBIT VS OCF VS FCFRIGL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M -40M -60M

1.2 Ratios

  • With an excellent Return On Assets value of 46.72%, RIGL belongs to the best of the industry, outperforming 99.23% of the companies in the same industry.
  • The Return On Equity of RIGL (96.34%) is better than 99.42% of its industry peers.
  • RIGL's Return On Invested Capital of 63.44% is amongst the best of the industry. RIGL outperforms 99.61% of its industry peers.
Industry RankSector Rank
ROA 46.72%
ROE 96.34%
ROIC 63.44%
ROA(3y)-18.12%
ROA(5y)-18.4%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
RIGL Yearly ROA, ROE, ROICRIGL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200 400

1.3 Margins

  • The Profit Margin of RIGL (40.17%) is better than 97.69% of its industry peers.
  • With an excellent Operating Margin value of 42.17%, RIGL belongs to the best of the industry, outperforming 99.04% of the companies in the same industry.
  • With an excellent Gross Margin value of 93.10%, RIGL belongs to the best of the industry, outperforming 93.45% of the companies in the same industry.
  • In the last couple of years the Gross Margin of RIGL has declined.
Industry RankSector Rank
OM 42.17%
PM (TTM) 40.17%
GM 93.1%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.38%
GM growth 5Y-1.87%
RIGL Yearly Profit, Operating, Gross MarginsRIGL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -500 -1K -1.5K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. RIGL Health Analysis

2.1 Basic Checks

  • RIGL has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
  • Compared to 1 year ago, RIGL has more shares outstanding
  • The number of shares outstanding for RIGL has been reduced compared to 5 years ago.
  • Compared to 1 year ago, RIGL has an improved debt to assets ratio.
RIGL Yearly Shares OutstandingRIGL Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M
RIGL Yearly Total Debt VS Total AssetsRIGL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

2.2 Solvency

  • RIGL has an Altman-Z score of -1.56. This is a bad value and indicates that RIGL is not financially healthy and even has some risk of bankruptcy.
  • The Altman-Z score of RIGL (-1.56) is comparable to the rest of the industry.
  • The Debt to FCF ratio of RIGL is 0.88, which is an excellent value as it means it would take RIGL, only 0.88 years of fcf income to pay off all of its debts.
  • The Debt to FCF ratio of RIGL (0.88) is better than 94.80% of its industry peers.
  • RIGL has a Debt/Equity ratio of 0.25. This is a healthy value indicating a solid balance between debt and equity.
  • Looking at the Debt to Equity ratio, with a value of 0.25, RIGL is doing worse than 65.90% of the companies in the same industry.
  • Although RIGL's pure debt/equity ratio does not look good, it has limited outstanding debt compared to the Free Cash Flow. We will not put too much weight on the debt/equity number as it may be because of low equity, which could be a consequence of a share buyback program for instance. This needs to be investigated.
Industry RankSector Rank
Debt/Equity 0.25
Debt/FCF 0.88
Altman-Z -1.56
ROIC/WACC6.95
WACC9.13%
RIGL Yearly LT Debt VS Equity VS FCFRIGL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M

2.3 Liquidity

  • A Current Ratio of 2.28 indicates that RIGL has no problem at all paying its short term obligations.
  • Looking at the Current ratio, with a value of 2.28, RIGL is doing worse than 73.60% of the companies in the same industry.
  • RIGL has a Quick Ratio of 2.14. This indicates that RIGL is financially healthy and has no problem in meeting its short term obligations.
  • RIGL has a worse Quick ratio (2.14) than 73.41% of its industry peers.
Industry RankSector Rank
Current Ratio 2.28
Quick Ratio 2.14
RIGL Yearly Current Assets VS Current LiabilitesRIGL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

7

3. RIGL Growth Analysis

3.1 Past

  • RIGL shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 4307.14%, which is quite impressive.
  • RIGL shows a strong growth in Revenue. In the last year, the Revenue has grown by 79.13%.
  • The Revenue has been growing by 24.77% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)4307.14%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%108.57%
Revenue 1Y (TTM)79.13%
Revenue growth 3Y6.31%
Revenue growth 5Y24.77%
Sales Q2Q%25.59%

3.2 Future

  • Based on estimates for the next years, RIGL will show a very strong growth in Earnings Per Share. The EPS will grow by 38.70% on average per year.
  • The Revenue is expected to grow by 15.91% on average over the next years. This is quite good.
EPS Next Y619.43%
EPS Next 2Y109.9%
EPS Next 3Y73.71%
EPS Next 5Y38.7%
Revenue Next Year69.07%
Revenue Next 2Y27.77%
Revenue Next 3Y22.37%
Revenue Next 5Y15.91%

3.3 Evolution

  • The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
RIGL Yearly Revenue VS EstimatesRIGL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 100M 200M 300M 400M
RIGL Yearly EPS VS EstimatesRIGL Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 5 -5

More info and screens

Find the best growth stocksShow best growing peers

10

4. RIGL Valuation Analysis

4.1 Price/Earnings Ratio

  • Based on the Price/Earnings ratio of 4.55, the valuation of RIGL can be described as very cheap.
  • 99.04% of the companies in the same industry are more expensive than RIGL, based on the Price/Earnings ratio.
  • RIGL's Price/Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 26.46.
  • A Price/Forward Earnings ratio of 6.78 indicates a rather cheap valuation of RIGL.
  • 98.46% of the companies in the same industry are more expensive than RIGL, based on the Price/Forward Earnings ratio.
  • When comparing the Price/Forward Earnings ratio of RIGL to the average of the S&P500 Index (24.65), we can say RIGL is valued rather cheaply.
Industry RankSector Rank
PE 4.55
Fwd PE 6.78
RIGL Price Earnings VS Forward Price EarningsRIGL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

  • RIGL's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. RIGL is cheaper than 99.23% of the companies in the same industry.
  • Compared to the rest of the industry, the Price/Free Cash Flow ratio of RIGL indicates a rather cheap valuation: RIGL is cheaper than 98.65% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF 7.48
EV/EBITDA 2.95
RIGL Per share dataRIGL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 5 10 15

4.3 Compensation for Growth

  • RIGL's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • The decent profitability rating of RIGL may justify a higher PE ratio.
  • A more expensive valuation may be justified as RIGL's earnings are expected to grow with 73.71% in the coming years.
PEG (NY)0.01
PEG (5Y)N/A
EPS Next 2Y109.9%
EPS Next 3Y73.71%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. RIGL Dividend Analysis

5.1 Amount

  • No dividends for RIGL!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

RIGL Fundamentals: All Metrics, Ratios and Statistics

RIGEL PHARMACEUTICALS INC

NASDAQ:RIGL (3/9/2026, 8:00:02 PM)

After market: 28.6001 +0.53 (+1.89%)

28.07

-0.8 (-2.77%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-02
Earnings (Next)05-04
Inst Owners91.09%
Inst Owner Change6.53%
Ins Owners3.09%
Ins Owner Change6.76%
Market Cap509.47M
Revenue(TTM)282.08M
Net Income(TTM)113.30M
Analysts80
Price Target47.94 (70.79%)
Short Float %21.57%
Short Ratio9.16
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)46.05%
Min EPS beat(2)24.64%
Max EPS beat(2)67.46%
EPS beat(4)4
Avg EPS beat(4)188.12%
Min EPS beat(4)24.64%
Max EPS beat(4)592.43%
EPS beat(8)7
Avg EPS beat(8)242.36%
EPS beat(12)11
Avg EPS beat(12)181.29%
EPS beat(16)14
Avg EPS beat(16)138.58%
Revenue beat(2)2
Avg Revenue beat(2)11.07%
Min Revenue beat(2)10.05%
Max Revenue beat(2)12.08%
Revenue beat(4)4
Avg Revenue beat(4)12.62%
Min Revenue beat(4)9.15%
Max Revenue beat(4)19.17%
Revenue beat(8)7
Avg Revenue beat(8)10.41%
Revenue beat(12)11
Avg Revenue beat(12)14.43%
Revenue beat(16)12
Avg Revenue beat(16)11.18%
PT rev (1m)0%
PT rev (3m)3.68%
EPS NQ rev (1m)7.09%
EPS NQ rev (3m)17.09%
EPS NY rev (1m)0.23%
EPS NY rev (3m)1.14%
Revenue NQ rev (1m)1.14%
Revenue NQ rev (3m)3.4%
Revenue NY rev (1m)0.27%
Revenue NY rev (3m)0.78%
Valuation
Industry RankSector Rank
PE 4.55
Fwd PE 6.78
P/S 1.81
P/FCF 7.48
P/OCF 7.47
P/B 4.33
P/tB 5.52
EV/EBITDA 2.95
EPS(TTM)6.17
EY21.98%
EPS(NY)4.14
Fwd EY14.75%
FCF(TTM)3.75
FCFY13.37%
OCF(TTM)3.76
OCFY13.38%
SpS15.54
BVpS6.48
TBVpS5.08
PEG (NY)0.01
PEG (5Y)N/A
Graham Number29.99
Profitability
Industry RankSector Rank
ROA 46.72%
ROE 96.34%
ROCE 80.3%
ROIC 63.44%
ROICexc 854.98%
ROICexgc N/A
OM 42.17%
PM (TTM) 40.17%
GM 93.1%
FCFM 24.16%
ROA(3y)-18.12%
ROA(5y)-18.4%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.38%
GM growth 5Y-1.87%
F-Score7
Asset Turnover1.16
Health
Industry RankSector Rank
Debt/Equity 0.25
Debt/FCF 0.88
Debt/EBITDA 0.25
Cap/Depr 1.57%
Cap/Sales 0.01%
Interest Coverage 17.61
Cash Conversion 56.17%
Profit Quality 60.14%
Current Ratio 2.28
Quick Ratio 2.14
Altman-Z -1.56
F-Score7
WACC9.13%
ROIC/WACC6.95
Cap/Depr(3y)424.8%
Cap/Depr(5y)301.24%
Cap/Sales(3y)4.48%
Cap/Sales(5y)3%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)4307.14%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%108.57%
EPS Next Y619.43%
EPS Next 2Y109.9%
EPS Next 3Y73.71%
EPS Next 5Y38.7%
Revenue 1Y (TTM)79.13%
Revenue growth 3Y6.31%
Revenue growth 5Y24.77%
Sales Q2Q%25.59%
Revenue Next Year69.07%
Revenue Next 2Y27.77%
Revenue Next 3Y22.37%
Revenue Next 5Y15.91%
EBIT growth 1Y1151.72%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year546.96%
EBIT Next 3Y91.91%
EBIT Next 5Y95.89%
FCF growth 1Y286.79%
FCF growth 3Y80.89%
FCF growth 5YN/A
OCF growth 1Y418.44%
OCF growth 3Y74.92%
OCF growth 5YN/A

RIGEL PHARMACEUTICALS INC / RIGL FAQ

What is the ChartMill fundamental rating of RIGEL PHARMACEUTICALS INC (RIGL) stock?

ChartMill assigns a fundamental rating of 7 / 10 to RIGL.


What is the valuation status for RIGL stock?

ChartMill assigns a valuation rating of 10 / 10 to RIGEL PHARMACEUTICALS INC (RIGL). This can be considered as Undervalued.


Can you provide the profitability details for RIGEL PHARMACEUTICALS INC?

RIGEL PHARMACEUTICALS INC (RIGL) has a profitability rating of 6 / 10.


How financially healthy is RIGEL PHARMACEUTICALS INC?

The financial health rating of RIGEL PHARMACEUTICALS INC (RIGL) is 7 / 10.